Replies to post #308034 on Anavex Life Sciences Corp (AVXL)

[boi568]

Part of the plan involves doubling the number of authorized shares.

[frrol]

Buyout interest, if and when it comes, is not a threat. It'll be great to see, and would be inevitable. What is not inevitable, despite tired tropes, is a meanie unfair buyout. It's very difficult to buy a valuable company "cheap" that doesn't want to be bought. There are simple reasons for this. They result in all successful biotechs staying independent or cooperatively getting bought at very high valuations. Don't worry about us being too beautiful. We're not. No one has even asked us on a date. We're too young. Might be soon though. Watch for trial results and possible regulatory decisions.

[BIOChecker4]

To keep things in perspective, Biogunk, as you call it, is one of the most successful biotech companies in the world, with a market cap of $41 billion, 4Q20 revenues of $2.85 billion, 4Q net income of $3.58 billion, and a share price of $262. Biogunk has 10 approved and marketed drugs and 3 more in partnership with Genentech. As well, they have 17 investigational drugs in clinical trials.

As we know, Biogunk took a look at A2-73 and that was that. Clearly, Biogunk has no interest in Anavex whatsoever, so you need not worry about any potential takeover.